.............. * V. .*-- H . ?..

l i5 1AK t JUB 5256 AG4 CCA KL-UA 1 V ff 'A__ b TART Jb 5256 AC477CCA RfcOA ACCT 04 77 V 1.44.45 PM 29 AUG B 4 PR1NTER2 SYS VBif2 JUB 5256 STARI A*4*+ 4 *'*"*A Sf ARf" "JU B"525 6 "04?

February 27, 1979 M O N SA N T O IN D U ST R IA L C H E M IC A L S CO. 8 0 0 N.

Monsanto M onunto Company BOO N.

=^========================================= Document: D:\NEV\LSG\DEPS\R0USH93.DS1 5 5-25 His residential address is 10 Babler Lane in St.

2/19/88 TO: W.

2/8/87 RE: Latest Draftings on Midland RA TO: Ad Hoc-ers FROM: Don Barnes -_ Last week, at the request of the Committee, I distributed copies of the Nov., 1986 draft of the Risk Assessment which is being prepared for Region 5 in relation to the ''dioxin" situation in Midland, MI.

4 ,4'-Thiodiphenol (TOP) 4 ,4'-SuIfonyidiphenol (SDP) Crown Zellerbach has developed considerable expertise in manufac turing symmetrical tliiobis aromatic compounds.

DR.

Pxtsij- D. .1. lwlii.

FROM E . d .

'pX'Z.o^S DIOXINS IN ENVIRONMENT, Chapter 20, Panel Discussion, Plaintiffs' Exhibit 1802: McConnell, page 271: "We have shown in animals that chronic low-level exposures in several species of animals appear to be more potent than a single equivalent dose.

3 February 2009 Draft Selection Criteria to identify Key In Vivo Mammalian Studies that Inform Dose-Response Modeling for 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)a Study Feature Chemical, purity, matrix/medium Peer review Study design, execution, and reporting Study subject: species, strain, and sensitivity for given endpoint; litter; life stage; gender Exposure route Dose level Exposure frequency, duration, and timing Controls Response Statistical evaluation Selection Rationale Primary*3 Secondary^ TCDD-only doses included, purity specified, TCDD purity or matrix not clearly identified matrix in which TCDD is administered is identified Independently peer-reviewed, publicly available Supplementary materials accompanying peer-reviewed publication Clearly documented and consistent with standard Testing protocol provides incomplete toxicological principles, testing protocols, coverage of relevant endpoint-specific and practice (i.e., endpoint-appropriate, measures, particularly for negative findings particularly for negative findings) Mammalian species Mammalian species, in vivo, but only Strain and gender identified studying an artificially sensitive subject Animal age at beginning of treatment identified (e.g., knockout mouse) Litter confounders (within/between) accounted for Currently Excluded Studies of dioxin-like compounds (DLCs) or mixtures Not formally peer-reviewed; literature not publicly available Studies not meeting standard principles and practices Non-mammalian or not in vivo Oral Parenteral (e.g., intravenous, intramuscular, Inhalation, dermal, ocular intraperitoneal, subcutaneous) Lowest dose <200 ng/kg-d for noncancer endpoints and <1 ^g)/kg-d for cancer Lowest dose >200 ng/kg-d for noncancer endpoints, or >1.0 ^.g/kg-d for cancer Dosing regimen characterized and explained Characterization/explanation missing or cannot be determined Appropriate and well characterized Effect reported, but with no negative control Effect relevant to human health Magnitude outside range of normal variability Precursor effects, or adaptive responses Lethality potentially relevant to human health Clearly described and appropriate to the endpoint Limited statistical context and study design (e.g., per error variance, magnitude of effect) a NAS (2006) commented that the selection of data sets for quantitative dose-response modeling needed to be more transparent.

Cable Viewer Viewing cable 05BRASILIA3026, SLOW GOING ON BIOTECH, BUT MONSANTO LOOKING AT If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others.

UNITED STATES OF AMERICA Before the SECURITIES AND EXCHANGE COMMISSION SECURITIES EXCHANGE ACT OF 1934 Release No. 56138 / July 26, 2007 ACCOUNTING AND AUDITING ENFORCEMENT Release No. 2658 / July 26, 2007 ADMINISTRATIVE PROCEEDING File No. 3-12712 In the Matter of DELTA & PINE LAND COMPANY and TURK DELTAPINE, INC., Respondents.I.